WaveMan
WaveMan · Company
BJDX · Bluejay Diagnostics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BJDX Bluejay Diagnostics (BJDX) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001704287
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter

What the filings say about BJDX

Insiders, 180 days
+$47.8K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan

Bluejay Diagnostics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Bluejay Diagnostics, Inc. insiders bought a net $47.8K of stock across 21 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HRT FINANCIAL LP
SELL
2026-07-13 SECtraded 2026-07-10
34,938
$48.9K
-53.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 9, 2026.
  • The trade is 38.0% of the 92,055 shares held after it.
  • No other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP sold about $48.9K of BJDX on Jul 10, 2026, the largest insider sale at the company on our record; 6 funds added in the latest 13F quarter.
HRT FINANCIAL LP
BUY
2026-07-13 SECtraded 2026-07-09
64,047
$96.7K
-53.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 50.4% of the 126,993 shares held after it.
  • No other insider bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRT FINANCIAL LP bought about $96.7K of BJDX on Jul 9, 2026, the largest insider purchase at the company on our record; 6 funds added in the latest 13F quarter.
Wurth Douglas Clark
Director
BUY
2026-05-18 SECtraded 2026-03-14
12,500
$25.0K
-66.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 17, 2022.
  • -13.3% median (-13.3% mean) 90-day return after 2 previous buys.
  • The trade is 99.1% of the 12,608 shares held after it.
  • 4 other insiders bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wurth Douglas Clark bought about $25.0K of BJDX on Mar 14, 2026, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.
Dey Indranil
President and CEO
BUY
2026-05-18 SECtraded 2026-03-14
12,500
$25.0K
-66.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 13, 2023.
  • -51.8% median (-57.6% mean) 90-day return after 3 previous buys.
  • The trade is 99.8% of the 12,522 shares held after it.
  • 4 other insiders bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Dey Indranil bought about $25.0K of BJDX on Mar 14, 2026, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.
CHASE DONALD R
Director
BUY
2026-05-18 SECtraded 2026-03-14
12,500
$25.0K
-66.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 99.8% of the 12,525 shares held after it.
  • 4 other insiders bought within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CHASE DONALD R bought about $25.0K of BJDX on Mar 14, 2026, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.
21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 16 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$47.8K over 180 days
+$47.8K of it by a 10%+ holder
more than 70% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 95% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$942.3K repurchased, FY to 2026-06-30
below 88% of Medical Devices
Short interest
3.3% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 51% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BJDX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-94.1%12M
-94%-63%-31%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-07-09 · HRT FINANCIAL LP bought $96.7K2026-07-10 · HRT FINANCIAL LP sold $48.9K2026-03-14 · Wurth Douglas Clark bought $25.0K2026-03-14 · Dey Indranil bought $25.0K2026-03-14 · CHASE DONALD R bought $25.0K2026-03-14 · ZEIDMAN FRED S bought $25.0K2026-03-14 · Dey Svetlana bought $25.0K2026-03-11 · Northstrive Fund II LP filed a 5%+ stake (1.13%)2026-03-11 · Braeden Lichti filed a 5%+ stake (3.65%)2026-03-11 · Braeden Lichti filed a 5%+ stake (3.65%)2026-03-11 · Northstrive Fund II LP filed a 5%+ stake (1.13%)2026-03-11 · Braeden Lichti filed a 5%+ stake (3.65%)2026-03-11 · Northstrive Fund II LP filed a 5%+ stake (1.13%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BJDX: institutional holders (13F)

13F holdings, latest reported quarter
ARMISTICE CAPITAL, LLC
131,000 sh
$157.2K
HEIGHTS CAPITAL MANAGEMENT, INC
35,400 sh
$42.5K
BOOTHBAY FUND MANAGEMENT, LLC
27,130 sh
$32.6K
BANK OF AMERICA CORP /DE/
10,337 sh
$12.4K
VANGUARD FIDUCIARY TRUST CO
10,225 sh
$12.3K

Congress trades in BJDX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Northstrive Fund II LP
Activist 13D · 2026-03-11
1.13%
Braeden Lichti
Activist 13D · 2026-03-11
3.65%
Braeden Lichti
Activist 13D · 2026-03-11
3.65%
Northstrive Fund II LP
Activist 13D · 2026-03-11
1.13%
Braeden Lichti
Activist 13D · 2026-03-11
3.65%

BJDX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BJDX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$53.8K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$392 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Not applicable
2 active
What changed recently
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
2026-10-01 · Completion moved 2026-09-30 → 2026-12-31
,
Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study
2026-09-30 · Recruiting → Active Not Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $47.8K bought by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BJDX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-98.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-81.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-99.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$249.0K
Gross profitn/an/an/a$48.9K
Operating income-$7.0M-$7.2M-$10.3M-$9.3M
Net income-$6.8M-$7.7M-$10.0M-$9.3M
EPS (diluted)-15.25-456.75-3,631.48-9.22
Operating cash flow-$6.1M-$7.8M-$8.3M-$7.7M
Cash$5.2M$4.3M$2.2M$10.1M
SEC XBRL, fiscal years, as known on 2026-10-28

BJDX Stock Sonar score 4/7 axes

Find similar shapesCompare

BJDX ranks highest on insider conviction (61st percentile) and risk and compliance (39th), and lowest on institutional and government (5th), among Medical Devices peers.

Profitability
22
Inputs
  • Return on equity-98.9% · 26 pct, sector of 183
  • Return on assets-81.1% · 23 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-99.7% · 19 pct, sector of 188
Insider conviction
61
Inputs
  • Net Form 4 buying (codes P and S), 180d$48K · 70 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
5
Inputs
  • Funds adding, latest quarter6 · 5 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+3.3% · 60 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+20.2% · 18 pct, sector of 198
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BJDX filings, in plain words

Are Bluejay Diagnostics insiders buying or selling BJDX?

In the 180 days to 2026-10-28, Bluejay Diagnostics insiders were net buyers, a net $47.8K: $96.7K of purchases and $48.9K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Bluejay Diagnostics insiders were net buyers of BJDX, a net $47.8K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $47.8K, came from a holder of 10% or more rather than an officer or director. The latest 5% ownership filing is a 13D by Northstrive Fund II LP, filed 2026-03-11, for 1.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies